Thallion Pharmaceuticals Inc. (TSX VENTURE:TLN) today announced its operational
and financial results for the 2013 first quarter ended February 28, 2013.
With the completion of the SHIGATEC Phase II trial and recently announced
decision to temporarily suspend the future development of its Shigamabs(R)
program, the Company has elected to restructure its organization and materially
reduce current expenditures during its ongoing strategic review process.
Effective this week, Thallion has reduced its clinical and administrative
headcount, representing the Company's most significant operating cost for its
2013 fiscal year, by approximately 70%. As a result, the Company will record a
one-time charge of approximately $550,000 in severance and termination costs for
the second quarter ended May 31, 2013.
"I would like to express my deepest gratitude to the employees of Thallion for
their professionalism and dedication to this Company", said Dr. Allan Mandelzys,
Chief Executive Officer of Thallion. "The management of Thallion remains
committed to minimizing the operational burn during the strategic review process
and to ultimately leverage our assets in a corporate transaction that is of the
greatest potential value to our shareholders."
Effective today, the Company has also announced that Mr. Roberto Bellini has
resigned from the Board of Directors in order to pursue other interests. He had
been a member of Thallion's Board since 2007. "On behalf of Thallion's Board and
management, I would like to thank Roberto for his deep commitment to the
Company, and for his guidance, thoughtfulness and important contributions
throughout his tenure", said Lloyd M. Segal, Thallion's Chairman.
Operational Highlights
-- The Special Committee comprised of independent directors of the Board
continues to actively evaluate potential corporate opportunities with a
view to maximizing shareholder value.
-- To limit operational spend during the strategic review process, the
Company has undergone a corporate restructuring and significantly
reduced headcount, subsequent to quarter end.
-- The Company has met the specific conditions under its indemnity
agreement with Premium Brands Holding Corporation and as such, the
irrevocable letter of credit in favour of Premium Brands was removed and
the Company's restricted cash position of $1,000,000 was reinstated as
unrestricted cash, subsequent to quarter end.
-- The Company closed out the SHIGATEC Phase II clinical study, subsequent
to quarter end.
-- Thallion has obtained court approval to delay the holding of its 2013
Annual General Meeting of Shareholders to be held by no later than
September 27, 2013, subsequent to quarter end.
-- Mr. Roberto Bellini resigned from the Company's Board of Directors
effective April 24, 2013.
Financial Highlights
Collaboration and licensing revenues for the three-month period ended February
28, 2013, were $9,656,256 compared to $616,557 for the three-month period ended
February 29, 2012. The increase in first quarter revenue is due to the early
termination of the development and license agreement with LFB in February 2013;
as the Company will no longer be continuing the development of Shigamabs(R)
under the agreement nor receiving any further payments, the deferred revenue
balance was recognized as collaboration and licensing revenues in the first
quarter of 2013.
Research and development (R&D) expenses before tax credits amounted to $470,203
in the first quarter of 2013, compared with $1,028,563 in the first quarter of
2012. The Company completed enrollment of the 45 patients recruited in the
SHIGATEC Phase II trial in January 2012, consequently the 54% decrease in R&D
costs is the result of reduced clinical trial expenditures, decreased costs
related to manufacturing activities and other miscellaneous cost reductions.
General and administrative expenses amounted to $641,547 in the first quarter of
2013 compared with $613,128 in the first quarter of 2012. This slight increase
is primarily the result of having collected $25,000 in proceeds from the
disposal of an asset held for sale in the first quarter of 2012.
The Company recorded net earnings of $8,771,812 or $0.27 per share in the first
quarter of 2013, compared with a net loss of $835,254 or $0.03 per share in the
first quarter of 2012. This increase in net earnings is primarily due to the
recognition of $9,656,256 in collaboration and licensing revenues as a result of
the early termination of the agreement with LFB, described above.
As at February 28, 2013, the Company's unrestricted cash position amounted to
$9,542,208, which consists of cash and short-term investments. The Company's
liquidity availability amounted to $10,544,945 compared with $11,289,797 on
November 30, 2012. The Company's working capital amounted to $9,832,624 as at
February 28, 2013, compared to $10,705,174 as at November 30, 2012, a decrease
of $872,550. The decreases in liquidity and working capital are primarily due to
activities related to the Company's first quarter 2013 operations.
As of April 24, 2013, the Company had 32,194,566 common shares outstanding and a
total of 3,676,450 stock options.
About Thallion Pharmaceuticals Inc.
Thallion Pharmaceuticals Inc. (TSX VENTURE:TLN) is a biotechnology company
developing pharmaceutical products in the areas of infectious disease and
oncology. The Company's lead clinical program Shigamabs(R) is a dual antibody
product for the treatment of Shiga toxin-producing E. coli bacterial infections
and has recently completed a Ph II clinical trial. Additional information about
Thallion can be obtained at www.thallion.com.
Forward-Looking Statements
This press release contains certain forward-looking statements, including,
without limitation, statements containing the words "believe", "may", "plan",
"will", "estimate", "continue", "anticipate", "intend", "expect" and other
similar expressions which constitute "forward-looking information" within the
meaning of applicable Canadian securities laws. Forward-looking statements
reflect Thallion's current expectation and assumptions, and are subject to a
number of risks and uncertainties that could cause actual results to differ
materially from those anticipated. These forward-looking statements involve
risks and uncertainties including, but not limited to, risks relating to the
outcome of the strategic review process. Given these risks and uncertainties,
readers are cautioned not to place undue reliance on such forward-looking
statements. Thallion undertakes no obligation to publicly update or revise any
forward-looking statements either as a result of new information, future events
or otherwise, except as required by applicable Canadian securities laws.
Financial results included below:
THALLION PHARMACEUTICALS INC.
Condensed Consolidated Statements of Financial Position
(unaudited)
----------------------------------------------------------------------------
----------------------------------------------------------------------------
February 28, November 30,
2013 2012
----------------------------------------------------------------------------
Assets
Current assets:
Cash $ 1,844,989 $ 7,236,228
Short-term investments 7,697,219 3,124,580
Foreign exchange forward contracts - 13,275
Sales tax receivable and other assets 61,542 28,650
Balance of sale receivable 601,306 605,675
Tax credits receivable 401,431 323,314
Deposits and prepaid expenses 51,763 153,553
----------------------------------------------------------------------------
10,658,250 11,485,275
Restricted cash 1,000,000 1,000,000
Property and equipment 34,584 36,306
----------------------------------------------------------------------------
1,034,584 1,036,306
----------------------------------------------------------------------------
$ 11,692,834 $ 12,521,581
----------------------------------------------------------------------------
----------------------------------------------------------------------------
Liabilities and Equity
Current liabilities:
Trade and other payables $ 825,626 $ 780,101
Deferred revenues - 9,656,256
Equity:
Share capital 115,512,823 115,512,823
Warrants 1,375,000 1,375,000
Contributed surplus 20,378,144 20,367,972
Deficit (126,398,759) (135,170,571)
----------------------------------------------------------------------------
Equity attributable to equity holders of the
Company 10,867,208 2,085,224
----------------------------------------------------------------------------
$ 11,692,834 $ 12,521,581
----------------------------------------------------------------------------
THALLION PHARMACEUTICALS INC.
Condensed Consolidated Statements of Earnings (Loss) and Comprehensive
Income (Loss)
(unaudited)
----------------------------------------------------------------------------
----------------------------------------------------------------------------
Three-month periods ended
--------------------------------
February 28, February 29,
2013 2012
----------------------------------------------------------------------------
Revenues
Collaboration and licensing revenues $ 9,656,256 $ 616,557
----------------------------------------------------------------------------
Expenses
Research and development 470,203 1,028,563
Tax credits (78,117) (94,882)
--------------------------------
392,086 933,681
General and administrative 641,547 613,128
Finance (income) costs
Interest income (17,323) (16,142)
Foreign exchange (gain) loss (153,541) 49,110
Changes in fair value of foreign
exchange forward contracts 21,675 (127,966)
----------------------------------------------------------------------------
884,444 1,451,811
----------------------------------------------------------------------------
Net earnings (loss) and comprehensive income
(loss) attributable to equity holders of
the Company $ 8,771,812 $ (835,254)
----------------------------------------------------------------------------
----------------------------------------------------------------------------
Basic and diluted earnings (loss) per share $ 0.27 $ (0.03)
----------------------------------------------------------------------------
THALLION PHARMACEUTICALS INC.
Condensed Consolidated Statements of Cash Flows
(unaudited)
----------------------------------------------------------------------------
----------------------------------------------------------------------------
Three-month periods ended
--------------------------------
February 28, February 29,
2013 2012
----------------------------------------------------------------------------
Cash flows used in operating activities:
Net earnings (loss) $ 8,771,812 $ (835,254)
Adjustments for:
Depreciation 2,663 3,255
Interest income (17,323) (16,142)
Interest received 16,472 19,780
Gain on disposal of property and equipment - (25,331)
Effect of exchange rate fluctuations on
cash held 918 95,433
Effect of exchange rate fluctuations on
balance of sale receivable (22,037) -
Recognition of deferred revenues (9,656,256) -
Decrease (increase) in fair value of open
foreign exchange forward contracts 13,275 (84,375)
Stock-based compensation 10,172 9,882
----------------------------------------------------------------------------
(880,304) (832,752)
Changes in operating assets and liabilities:
Sales tax receivable and other assets (32,041) (13,336)
Tax credits receivable (78,117) (94,882)
Deposits and prepaid expenses 21,694 19,119
Trade and other payables 125,621 (491,523)
Provisions - (55,224)
Deferred revenues - 414,059
----------------------------------------------------------------------------
37,157 (221,787)
----------------------------------------------------------------------------
(843,147) (1,054,539)
----------------------------------------------------------------------------
Cash flows (used in) from investing
activities:
Proceeds from disposal of investment in
Caprion Proteomics Inc. 26,406 -
Acquisition of short-term investments (6,556,903) (1,010,186)
Proceeds from disposal/maturity of short-
term investments 1,984,264 1,000,000
Additions to property and equipment (941) -
Proceeds from disposal of property and
equipment - 25,331
----------------------------------------------------------------------------
(4,547,174) 15,145
----------------------------------------------------------------------------
Net decrease in cash (5,390,321) (1,039,394)
Cash, beginning of period 7,236,228 5,005,687
Effect of exchange rate fluctuations on cash
held (918) (95,433)
----------------------------------------------------------------------------
Cash, end of period $ 1,844,989 $ 3,870,860
----------------------------------------------------------------------------
FOR FURTHER INFORMATION PLEASE CONTACT:
Thallion Pharmaceuticals Inc.
Michael Singer
Chief Financial Officer
(514) 940-3600
(514) 336-2343 (FAX)
info@thallion.com
www.thallion.com
Thallion Pharmaceuticals (TSXV:TLN)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Thallion Pharmaceuticals (TSXV:TLN)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024
